Director/PDMR Shareholding

18 Sep 2006 10:01

Alliance Pharma PLC18 September 2006 For immediate release 18 September 2006 ALLIANCE PHARMA PLC ("Alliance Pharma" or "the Company") Director Share Purchase Alliance Pharma plc (AIM: APH), the emerging speciality pharmaceutical company,announces that Andrew Smith, A Non-Executive Director of the Company hasacquired 60,000 ordinary shares in the Company at 16p per share bringing histotal holding to 60,000 ordinary, equivalent to 0.04 per cent of the Company'sissued share capital. For further information: Alliance Pharma plc + 44 (0) 1249 466966 John Dawson, Chief ExecutiveMaddy Scott, Finance Directorwww.alliancepharma.co.uk Buchanan Communications + 44 (0) 20 7466 5000 Mark Court/Lisa Baderoon/Rebecca Dietrich Notes to editors About Alliance Pharma Alliance Pharma, founded in 1996, is an AIM listed speciality pharmaceuticalcompany based in Chippenham, Wiltshire, UK. The company has a strong trackrecord of acquiring the rights to established niche brands and owns, or shares,the rights to 34 branded pharmaceutical products and continues to exploreopportunities to expand the range. Alliance Pharma's products are prescribed in the treatment of a wide range ofconditions and include brands used in periodontitis (a serious gum disease), theprevention of heart disease, in Parkinson's disease, in nutrition, in nasalinfections, in the treatment of dermatological conditions and in childbirth.Alliance Pharma's sales are mainly prescription driven. Its products aredistributed to hospitals directly and to UK and International pharmaceuticalwholesalers which service both hospital and retail pharmacies with theirprescription requirements. Alliance Pharma is also developing Posidorm for sleep disorders and Isprelor forthe induction of labour. Alliance Pharma joined the AIM market of the London Stock Exchange in December2003 and trades under the symbol APH. This information is provided by RNS The company news service from the London Stock Exchange